Myriad Genetics (MYGN) 10-Q2019 Q1 Quarterly report

Filed: 7 Nov 18, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: added, antidilutive, branch, Circuit, claim, commitment, concurrent, Conpany, constrained, contractor, contractual, convertible, Cook, Counsyl, County, deficient, disposition, earliest, entry, environment, expedient, experience, expertise, forecast, foregoing, forfeited, Fraud, fulfill, implementation, implemented, inhibitor, insufficient, intervene, invoiced, iv, Journal, jurisdiction, lack, landmark, large, leader, led, liquid, longer, maximum, Melanoma, metastatic, MN, modification, Motion, multiple, mutation, myPath, Occasionally, PARP, payback, Pfizer, Pipe, practical, practice, Prenatal, protein, published, purportedly, pursue, putative, qui, readily, recasting, reclassification, release, released, remediated, remediating, reproductive, rest, restated, RoW, satisfying, screening, served, software, talazoparaib, tam, Topic, treble, uncertainty, unclassified, unknown, upgrade, variant, vast, Vectra, volume, week, women

Removed: accrual, anxiety, classification, combination, commercialized, congruent, correct, database, decreased, demonstrating, disorder, disqualification, disqualified, dramatically, earlier, endpoint, equipment, error, exercise, fluctuate, foundation, generalized, growth, historically, identified, improperly, improved, indemnification, indirect, IRS, lost, March, mix, neuroscience, overstated, pipeline, policy, preventative, prospective, randomized, RCT, receiving, recreate, responsibility, riskScore, significantly, staging, statistically, swingline, understated, unit, updated, VectraDA, viability

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated MYGN transcripts

MYGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Myriad Genetics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 6, 2018		Date: November 6, 2018
By:	/s/ Mark C. Capone	By:	/s/ R. Bryan Riggsbee
Mark C. Capone		R. Bryan Riggsbee
President and Chief Executive Officer		Executive Vice President, Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.